Literature DB >> 15009457

Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism.

J Leurs1, V Nerme, Y Sim, D Hendriks.   

Abstract

In an in vitro clot lysis model in human plasma, carboxypeptidase U (CPU) is generated by thrombin following the coagulation and by plasmin at the later stage of clot lysis. CPU is able to slow down clot lysis by suppressing the cofactor activity of partially degraded fibrin in the plasminogen activation by tissue-type plasminogen activator (t-PA). Making use of thrombomodulin and a thrombin inhibitor, the generation of CPU during the in vitro clot lysis can be manipulated both in terms of magnitude and time course. The data obtained demonstrate that CPU affects the clot dissolution through a threshold-dependent mechanism: as long as the CPU activity remains above the threshold value, lysis is prevented from proceeding into the propagation phase. From the moment the CPU activity drops below this threshold value, the rate of lysis accelerates. This threshold value for CPU activity is dictated by the t-PA concentration: increasing the t-PA concentration increases the CPU threshold and vice versa. This implies that the effect of the CPU pathway will become more apparent at a lower fibrinolytic capacity. Our threshold-based hypothesis indicates that the time course of proCPU activation, the stability of CPU and the t-PA concentration all play a crucial role in determining the result of the in vitro clot lysis experiment. Furthermore, this hypothesis provides us with new insights into previously published data on the effects of CPU on in vitro clot lysis by high and low t-PA concentrations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009457     DOI: 10.1111/j.1538-7836.2004.00605.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  18 in total

1.  Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.

Authors:  Xianzhen Hu; Rick A Wetsel; Theresa N Ramos; Stacey L Mueller-Ortiz; Trenton R Schoeb; Scott R Barnum
Journal:  Immunobiology       Date:  2013-08-23       Impact factor: 3.144

2.  Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.

Authors:  Jonathan H Foley; Paula Kim; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-02-05       Impact factor: 5.157

3.  Catalytic Asymmetric Total Synthesis of (-)-Actinophyllic Acid.

Authors:  Lingchao Cai; Kui Zhang; Ohyun Kwon
Journal:  J Am Chem Soc       Date:  2016-03-04       Impact factor: 15.419

4.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

5.  Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.

Authors:  Yuko Suzuki; Hideto Sano; Liina Mochizuki; Naoki Honkura; Tetsumei Urano
Journal:  Blood Adv       Date:  2020-11-10

6.  Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites.

Authors:  Jonathan H Foley; Paul F Cook; Michael E Nesheim
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

7.  Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.

Authors:  Masahiro Ieko; Mika Yoshida; Sumiyoshi Naito; Toru Nakabayashi; Kaoru Kanazawa; Kazuhiro Mizukami; Masaya Mukai; Tatsuya Atsumi; Takao Koike
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

Review 8.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

9.  Thrombin activatable fibrinolysis inhibitor : its role in slow coronary flow.

Authors:  M N Yildirim; Y Selcoki; S Uysal; A B Nacar; B Demircelik; H I Aydin; B Eryonucu
Journal:  Herz       Date:  2013-09-27       Impact factor: 1.443

10.  The Utility and Potential of Mathematical Models in Predicting Fibrinolytic Outcomes.

Authors:  Brittany E Bannish; Nathan E Hudson
Journal:  Curr Opin Biomed Eng       Date:  2021-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.